ATM and cancer: The present findings, although limited by the small effect size, suggest that further analyses using a larger number of breast cancer patients treated with metformin should verify whether a pharmacogenomic profile including the analysis of ATM SNP rs11212617 genotype might deserve consideration as a predictive clinical biomarker to inform the personalized use of metformin in a cancer setting.